Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Is It Good for You? Amyloid Shows New Side in Mammalian Cells
1 December 2005. The amyloid protein conformation, a structure that propagates as insoluble fibrils of aggregated β-strand-containing peptides, is a common feature of many neurodegenerative diseases. In Alzheimer, Parkinson, and Huntington diseases, as well as in prion diseases, toxic amyloids or their precursors are blamed for all manner of neuropathology. In fact, most researchers have never met a nonpathogenic amyloid in higher animals and tend to view the protein fold as a bad seed, a carryover from evolution with no physiologically redeeming features.

That view may have to change, now that Jeffery Kelly and colleagues at the Scripps Research Institute in San Diego have discovered an abundant amyloid protein structure that functions in normal pigment production in mammalian cells. In the 29 November PloS online, the researchers report that amyloid fibers of the Pmel17 protein pack melanosomes, organelles that produce the protective pigment melanin. The amyloid provides a scaffold for the polymerization of tyrosine derivatives into melanin, accelerating the process and possibly protecting cells from the toxic effects of reactive melanin precursors. These results show for the first time a nonpathological role of amyloid, and suggest that this much-maligned conformation may, in fact, be an evolutionarily conserved motif with a number of physiological functions.

Melanin, the stuff of suntans and the body’s main defense against ionizing radiation, is produced inside membrane-bound melanosomes that are then transferred intact to neighboring cells. Melanosome maturation requires Pmel17, a transmembrane glycoprotein that is processed in melanosomes to release fragments (Mα), which then self-assemble into fibers. Present in many organisms, from fungi and insects to humans, Pmel17 is known to be essential for pigmentation in mice, chicken, and zebrafish.

Douglas Fowler and Atanas Koulov, co-first authors on the paper, used dye binding and biophysical techniques to show that Pmel17 fibers in melanosomes adopt an amyloid structure. In purified melanosomes from cow retina, Mα fibers bound both thioflavin S and Congo red, two amyloidophilic dyes. The fibers were detergent-resistant, but could be destroyed by boiling in 10 percent SDS, characteristic of a stable amyloid structure.

When the researchers expressed and purified recombinant Mα in bacteria, they found that the fragment spontaneously self-assembled into amyloid in vitro. The fibrillization was fast, at least four orders of magnitude faster than observed with the Alzheimer Aβ peptide or synuclein. Biophysical measurements, including electron microscopy, x-ray diffraction, and circular dichroism measurements were all consistent with the presence of the amyloid cross-β structure.

The function of the Pmel17 amyloid was revealed by experiments that simulated melanin production in vitro. Melanin is formed by polymerization of highly reactive tyrosine derivates, and the presence of Mα fibers sped up this polymerization. Interestingly, the structure of the melanin precursor indole-5,6-quinone (DHQ) resembles the core structure of thioflavin T, which might explain its avid binding to the Pmel17 amyloid. Also, Aβ and synuclein amyloids could also accelerate melanin production in vivo, suggesting that the presence of the cross-β sheet structure was the salient feature that enhanced polymerization.

Since amyloid formation is a highly toxic process for cells, why don’t melanocytes suffer consequences from harboring such a nasty player? The authors speculate that the secret lies in the way that functional amyloid formation occurs under optimized, controlled circumstances. The trafficking Pmel17 restricts its cleavage to melanosomes, thus sequestering the amyloidogenic Mα peptide inside a membrane-limited organelle. Also, the rapid kinetics of amyloid formation may serve to protect cells from damage by amyloid precursors. Compared to Pmel17’s tidy process, the extracellular formation of amyloid in neurodegenerative diseases seems downright disorderly, and more studies of this contrast may lead to new insights into pathogenic amyloid formation. Right off, the discovery of physiological amyloid in mammalian cells raises some new questions about possible pitfalls to using nonselective inhibitors of amyloid formation to treat such diseases.

The authors believe that Pmel17 is just the tip of a functional amyloid iceberg. They propose using the name “amyloidin” for nontoxic, useful amyloid, with the expectation that many more examples of this type of structure will be forthcoming.—Pat McCaffrey.

Reference:
Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional Amyloid Formation within Mammalian Tissue. PLoS Biol. 2005 Nov 29;4(1):e6 [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
  Primary Papers: Functional amyloid formation within mammalian tissue.

Comment by:  David Teplow
Submitted 13 December 2005  |  Permalink Posted 13 December 2005

Functional amyloid and nonfunctional interpretations
Fowler et al. report results of studies of the biophysical behavior of the bovine melanosome protein Pmel17 and of the potential role of this protein in melanin biosynthesis. The data strongly support the conclusion that Pmel17, under appropriate conditions, rapidly assembles into amyloid-type polymers and that these polymers support melanin synthesis. The demonstration of a physiologically beneficial role of Pmel17 amyloid adds another example to a growing list of prokaryotic and eukaryotic proteins for which amyloid formation serves an important role in normal cellular function. In some respects, however, the authors' view of the relative importance of these findings to larger questions of prokaryotic and eukaryotic cell biology and the role of amyloid is unsupported experimentally and thus must be considered "nonfunctional."

One of the most interesting observations of Fowler et al. was the rate of amyloid formation by Pmel17 (a half-time of roughly 1 second). This rate was four orders of magnitude...  Read more


  Comment by:  John Trojanowski, ARF Advisor
Submitted 16 January 2006  |  Permalink Posted 23 January 2006
  I recommend the Primary Papers

This paper and comment draw attention to other types of physiological amyloids or fibrillar structures that subserve normal funcitons. Examples include the elastins (e.g. Tamburro AM et al., J Biol Chem. 2005 Jan 28;280(4):2682-90. Epub 2004 Nov 18), as well as the complex network of filaments (from actin microfilaments to intermediate filaments) that also provide a scaffold and other functions needed by nearly all cell types. The existence of these normal filamentous poylmers that promote cell function and viablitiy will help dissect out how and why abnormal amyloid filaments exert deleterioius, pathological effects. It will also help us address the question of when, and by what mechanisms, they might serve a protective function in disease states.

View all comments by John Trojanowski

  Comment by:  PATRICIA ESTANI
Submitted 11 November 2008  |  Permalink Posted 14 November 2008
  I recommend the Primary Papers
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad